Guangdong Province Cerebrovascular Disease Translational Medicine Innovation Platform
The Guangdong Province Cerebrovascular Disease Translational Medicine Innovation Platform, also known as the Cerebrovascular Disease Platform, is Shenzhen's first and only provincial-level cerebrovascular translational medicine research platform. It boasts comprehensive research conditions and software support, and has established close cooperative relationships with several renowned research institutions in Shenzhen. The platform is led by Shenzhen Second People's Hospital, with participating units including the Brain Science Research Center of Southern University of Science and Technology, the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences, the Shenzhen Institute of Neuroscience, and the Shenzhen Brain Research Institute.
The platform encompasses six sub-specialties, covering areas such as blood-brain barrier damage, neural function plasticity and repair, the application of nanobiomaterials, neuroimaging, and language function rehabilitation. The research team has excellent scientific research work conditions and has completed the construction of four sub-platforms for cerebrovascular research, which include:
Cerebrovascular Disease Cell Culture Platform
Cerebrovascular Disease Animal Model Platform
Cerebrovascular Disease Clinical Translation Platform
Small Animal Neurological Function Evaluation Platform
These platforms are equipped with various instruments and facilities needed for cerebrovascular research, such as animal models of stroke, small animal vital sign monitoring, brain stereotaxic instruments, laser Doppler brain blood flow monitoring, and neurological function rating instruments, along with animal housing compatible with experimental needs.
Over the past three years, the platform has achieved significant research outputs, including:
Publication of 34 SCI papers with a cumulative impact factor of 225, including 18 papers with impact factors above 5, 7 papers with impact factors above 10, and 18 papers in the JCR first quartile.
Approval of 4 National Natural Science Foundation projects and 2 postdoctoral funds.
Receiving the second prize of the Guangdong Science and Technology Progress Award.
Authorization of 11 invention patents.
Publication of 1 monograph.
Training of 4 postdoctoral researchers.
The core members of the research team all hold doctoral degrees and have been recognized as high-level talents in Shenzhen and "Peacock Plan" overseas high-level talents. They have accumulated extensive experience in cerebrovascular disease research, with a well-structured team comprising members with backgrounds in clinical medicine, pharmacy, bioengineering, and nanobiomaterials. This multidisciplinary expertise facilitates comprehensive research on stroke and fosters the translation of research findings into practical applications. The team actively engages in translating research outcomes and has established close collaborations with several companies, striving to build an industry-oriented translational platform in the future, integrating production, education, medicine, research, and application.
Intrinsic Causes of Neurodegenerative Diseases:Utilizing cell and animal models to study underlying causes, elucidating new molecular signaling pathways, exploring and identifying new drug targets, and developing new treatments.
Neurodegenerative Disease Mechanisms:Investigating immune inflammation and metabolic molecular mechanisms.
Biomarkers for Early Diagnosis:Identifying biomarkers for early diagnosis and monitoring clinical drug trial efficacy, including brain imaging markers and body fluid molecular biomarkers.
Stem Cell and Brain Organoid Research:Conducting translational research on adult stem cells and brain organoids for treating brain diseases.
Drug Screening:Establishing a library of potential small molecule compounds and a high-throughput screening platform.
Clinical Trials:Conducting and coordinating clinical trials for treating brain diseases.
Achievements:
Animal Models and Platforms:Established platforms for neurodegenerative disease models in animals, including transgenic and gene knockout mice and rats, along with small animal neurological function evaluation platforms. Equipped with essential instruments for monitoring small animal vital signs, brain stereotaxic instruments, laser Doppler brain blood flow monitoring, and neurological function rating, as well as animal housing facilities.
Research Team:Led by high-level talents from Shenzhen, the core team members are experienced professionals with Ph.D. and master's degrees in related fields. They have made original breakthroughs in several fundamental and clinical areas, such as immune inflammation regulation and mitochondrial homeostasis in Alzheimer's disease, ubiquitination and ER-mitochondrial autophagy in ischemic stroke, and integrated diagnosis and treatment of stroke using aggregation-induced emission (AIE).
Research Outputs (up to November 2021):
Publications:33 SCI papers with a cumulative impact factor of 225, including 18 papers with impact factors above 5, 7 papers with impact factors above 10, and 18 JCR first quartile papers.
Funding:Secured multiple grants, including 2 National Natural Science Foundation (NSFC) general projects, 2 NSFC youth projects, 2 postdoctoral funds, 1 Shenzhen Key Basic Research Project, and 2 Shenzhen Basic Research Projects.
Awards: Awarded the second prize in the Guangdong Science and Technology Progress Awards in 2020.
Patents and Publications: Secured 9 invention patents and published one monograph.
Training:Trained 3 postdoctoral researchers.
Tang Yizhe's Team:
Funding and Projects:Obtained 2 general NSFC projects, 2 NSFC youth projects, 2 postdoctoral fund, 4 Guangdong general projects, and 5 Shenzhen Basic Research Projects. Conducted 1 clinical trial.
Training:Trained 6 postdoctoral researchers.
